• 1
    Kleihues P, Burger PC, Scheithauer BW, Zülch KJ. Histological typing of tumours of the central nervous system, 2nd edn. New York: Springer-Verlag, 1993.
  • 2
    Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 1998; 88: 110.
  • 3
    Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science 1991; 252: 165762.
  • 4
    Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev 1999; 18: 45164.
  • 5
    Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998; 16: 220212.
  • 6
    Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P, Lazzaro B, Nair S, McCormack T, Nieves J, Morabito M, Eshleman J. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992; 22: 22530.
  • 7
    Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, Pastan I, Zalutsky MR, Bigner DD. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin Cancer Res 1999; 5: 153949.
  • 8
    Wikstrand CJ, Bigner SH, Bigner DD. Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res 1983; 43: 332734.
  • 9
    Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80: 231520.
  • 10
    Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12: 43355.
  • 11
    Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, Cochran JR, Heinzelman P, Colby D, Swers J, Graff C, Wiley HS, et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 2003; 21: 16370.
  • 12
    Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 1999; 5: 264652.
  • 13
    Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 34028.
  • 14
    Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science 1991; 254: 11737.
  • 15
    Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci USA 1986; 83: 13204.
  • 16
    Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 1992; 267: 124203.
  • 17
    FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I. Recombinant immunotoxins for treating cancer. Int J Med Microbiol 2004; 293: 57782.
  • 18
    Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000; 6: 32634.
  • 19
    Frankel AE, Neville DM, Bugge TA, Kreitman RJ, Leppla SH. Immunotoxin therapy of hematologic malignancies. Semin Oncol 2003; 30: 54557.
  • 20
    Gram H, Marconi LA, Barbas CF, III, Collet TA, Lerner RA, Kang AS. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci USA 1992; 89: 357680.
  • 21
    Low NM, Holliger PH, Winter G. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J Mol Biol 1996; 260: 35968.
  • 22
    Yelton DE, Rosok MJ, Cruz G, Cosand WL, Bajorath J, Hellstrom I, Hellstrom KE, Huse WD, Glaser SM. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J Immunol 1995; 155: 19942004.
  • 23
    Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF, III. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 1995; 254: 392403.
  • 24
    Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci USA 1998; 95: 603742.
  • 25
    Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999; 17: 56872.
  • 26
    Beers R, Chowdhury P, Bigner D, Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 2000; 6: 283543.
  • 27
    Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002; 8: 9951002.
  • 28
    Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 2005; 280: 60717.
  • 29
    Loging WT, Lal A, Siu IM, Loney TL, Wikstrand CJ, Marra MA, Prange C, Bigner DD, Strausberg RL, Riggins GJ. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 2000; 10: 1393402.
  • 30
    Rich JN, Shi Q, Hjelmeland MD, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003; 278: 1595157.
  • 31
    Kuan CT, Wakiya K, Dowell JM, Herndon JE, II, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006; 12: 197082.
  • 32
    Capone PM, Papsidero LD, Chu TM. Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors. J Natl Cancer Inst 1984; 72: 6737.
  • 33
    Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, Prospero TD, Hoogenboom HR, Nissim A, Cox JPL, Harrison JL, Zaccolo M, Gherardi M, Winter G. Isolation of high affinity human antibodies directly from large synthetic repertoires. Embo J 1994; 13: 324560.
  • 34
    Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ, Bloemers HP. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 1995; 60: 7381.
  • 35
    Amersdorfer P, Marks JD. Phage libraries for generation of anti-botulinum scFv antibodies. Methods Mol Biol 2000; 145: 21940.
  • 36
    Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997; 57: 413040.
  • 37
    Batra JK, FitzGerald D, Gately M, Chaudhary VK, Pastan I. Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells. J Biol Chem 1990; 265: 15198202.
  • 38
    Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF, Wikstrand CJ. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 1981; 40: 20129.
  • 39
    Friedman HS, Houghtones PJ, Schold SC, Keir S, Bigner DD. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1994; 34: 17174.
  • 40
    Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12: 137382.
  • 41
    Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 1996; 93: 1481520.
  • 42
    Letourneur F, Klausner RD. A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell 1992; 69: 114357.
  • 43
    Neuberger MS, Milstein C. Somatic hypermutation. Curr Opin Immunol 1995; 7: 24854.
  • 44
    de Wildt RM, Hoet RM, van Venrooij WJ, Tomlinson IM, Winter G. Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J Mol Biol 1999; 285: 895901.
  • 45
    Ding D, Kanaly CW, Bigner DD, Cummings TJ, Herndon JE, II, Pastan I, Raghavan R, Sampson JH. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1–1. J Neuro-oncol 2010; 98: 17.